Cervicovaginal safety of the formulated, biguanide-based human immunodeficiency virus type 1 (HIV-1) inhibitor NB325 in a murine model

Journal of Biomedicine and Biotechnology

Volumn 2011, Issue , 2011, Pages

  Lozenski, Karissa ^a   Kish Catalone, Tina ^b   Pirrone, Vanessa ^a   Rando, Robert F ^c,d   Labib, Mohamed ^c   Wigdahl, Brian ^a   Krebs, Fred C ^a  

^a DREXEL UNIVERSITY COLLEGE OF MEDICINE   (United States)

^b DESALES UNIVERSITY   (United States)

^c Novaflux Biosciences Inc   (United States)

^d Medisys Health Communications   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; BIGUANIDE; HYDROXYETHYLCELLULOSE; MICROBICIDE; NB 325; UNCLASSIFIED DRUG; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; BIGUANIDE DERIVATIVE; NB325;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DRUG EXPOSURE; DRUG FORMULATION; DRUG SAFETY; FEMALE; HUMAN IMMUNODEFICIENCY VIRUS 1; IN VIVO STUDY; MOUSE; NONHUMAN; UTERINE CERVIX DISEASE; UTERINE CERVIX EPITHELIUM; VAGINA DISEASE; VAGINA EPITHELIUM; VIRUS INHIBITION; ANIMAL; DISEASE MODEL; DRUG EFFECT; DRUG TOXICITY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INTRAVAGINAL DRUG ADMINISTRATION;

HUMAN IMMUNODEFICIENCY VIRUS 1; MURINAE; MUS;

ADMINISTRATION, INTRAVAGINAL; ANIMALS; ANTI-HIV AGENTS; BIGUANIDES; DISEASE MODELS, ANIMAL; DRUG TOXICITY; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; MICE;

EID: 84855174178     PISSN: 11107243     EISSN: 11107251     Source Type: Journal    
DOI: 10.1155/2011/941061     Document Type: Article

References (32)

1. Joint United Nations Programme on HIV/AIDS (UNAIDS), Global report: UNAIDS report on the global AIDS epidemic 2010. 2010, http://www.unaids.org/ globalreport/Globalreport.htm
2. Balzarini J., Van Damme L., Microbicide drug candidates to prevent HIV infection Lancet 2007 369 9563 787 797 (Pubitemid 46335821)
3. Ramjee G., Microbicide research: current and future directions Current Opinion in HIV and AIDS 2010 5 4 316 321
4. Nuttall J., Microbicides in the prevention of HIV infection: current status and future directions Drugs 2010 70 10 1231 1243
5. Zydowsky T. M., Microbicides: chemistry, structure, and strategy Current Opinion in HIV and AIDS 2008 3 5 548 553
6. Ramjee G., Kamali A., McCormack S., The last decade of microbicide clinical trials in Africa: from hypothesis to facts AIDS 2010 24 4 S40 S49
7. Karim Q. A., Karim S. S. A., Frohlich J. A., Grobler A. C., Baxter C., Mansoor L. E., Kharsany A. B. M., Sibeko S., Mlisana K. P., Omar Z., Gengiah T. N., Maarschalk S., Arulappan N., Mlotshwa M., Morris L., Taylor D., Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women Science 2010 329 5996 1168 1174
8. Krebs F. C., Miller S. R., Ferguson M. L., Labib M., Rando R. F., Wigdahl B., Polybiguanides, particularly polyethylene hexamethylene biguanide, have activity against human immunodeficiency virus type 1 Biomedicine and Pharmacotherapy 2005 59 8 438 445 (Pubitemid 41383837)
9. Shubair M., Stanek R., White S., Larsen B., Effects of chlorhexidine gluconate douche on normal vaginal flora Gynecologic and Obstetric Investigation 1992 34 4 229 233 (Pubitemid 23023100)
10. Stray-Pedersen B., Bergan T., Hafstad A., Normann E., Grgaard J., Vangdal M., Vaginal disinfection with chlorhexidine during childbirth International Journal of Antimicrobial Agents 1999 12 3 245 251 (Pubitemid 29335936)
11. Overbosch D., Schilthuis H., Bienzle U., Behrens R. H., Kain K. C., Clarke P. D., Toovey S., Knobloch J., Nothdurft H. D., Shaw D., Roskell N. S., Chulay J. D., Boraston S., Salzman J., Tessier D., Goud T. J. L. M., Fleischer K., Peters M., Zieger B., Waner S., Brook P. E., Atovaquone-proguanil versus mefloquine for malaria prophylaxis in nonimmune travelers: results from a randomized, double-blind study Clinical Infectious Diseases 2001 33 7 1015 1021 (Pubitemid 32907104)
12. Keeven J., Wrobel S., Portoles M., DeCicco B. T., Evaluating the preservative effectiveness of RGP lens care solutions CLAO Journal 1995 21 4 238 241
13. Kirpichnikov D., McFarlane S. I., Sowers J. R., Metformin: an update Annals of Internal Medicine 2002 137 1 25 33 (Pubitemid 34705373)
14. Lee W. R., Tobias K. M., Bemis D. A., Rohrbach B. W., In vitro efficacy of a polyhexamethylene biguanide-impregnated gauze dressing against bacteria found in veterinary patients Veterinary Surgery 2004 33 4 404 411 (Pubitemid 41783015)
15. Motta G. J., Milne C. T., Corbett L. Q., Impact of antimicrobial gauze on bacterial colonies in wounds that require packing Ostomy/Wound Management 2004 50 8 48 62
16. Rosin M., Welk A., Bernhardt O., Ruhnau M., Pitten F. A., Kocher T., Kramer A., Effect of a polyhexamethylene biguanide mouthrinse on bacterial counts and plaque Journal of Clinical Periodontology 2001 28 12 1121 1126 (Pubitemid 33755218)
17. Passic S. R., Ferguson M. L., Catalone B. J., Kish-Catalone T., Kholodovych V., Zhu W., Welsh W., Rando R., Howett M. K., Wigdahl B., Labib M., Krebs F. C., Structure-activity relationships of polybiguanides with activity against human immunodeficiency virus type 1 Biomedicine and Pharmacotherapy 2010 64 10 723 732
18. Thakkar N., Pirrone V., Passic S., Zhu W., Kholodovych V., Welsh W., Rando R. F., Labib M. E., Wigdahl B., Krebs F. C., Specific interactions between the viral coreceptor CXCR4 and the biguanide-based compound NB325 mediate inhibition of human immunodeficiency virus type 1 infection Antimicrobial Agents and Chemotherapy 2009 53 2 631 638
19. Thakkar N., Pirrone V., Passic S., Keogan S., Zhu W., Kholodovych V., Welsh W., Rando R., Labib M., Wigdahl B., Krebs F. C., Persistent interactions between biguanide-based compound NB325 and CXCR4 result in prolonged inhibition of human immunodeficiency virus type 1 infection Antimicrobial Agents and Chemotherapy 2010 54 5 1965 1972
20. Catalone B. J., Kish-Catalone T. M., Budgeon L. R., Neely E. B., Ferguson M., Krebs F. C., Howett M. K., Labib M., Rando R., Wigdahl B., Mouse model of cervicovaginal toxicity and inflammation for preclinical evaluation of topical vaginal microbicides Antimicrobial Agents and Chemotherapy 2004 48 5 1837 1847 (Pubitemid 38544396)
21. Catalone B. J., Kish-Catalone T. M., Neely E. B., Budgeon L. R., Ferguson M. L., Stiller C., Miller S. R., Malamud D., Krebs F. C., Howett M. K., Wigdahl B., Comparative safety evaluation of the candidate vaginal microbicide C31G Antimicrobial Agents and Chemotherapy 2005 49 4 1509 1520 (Pubitemid 40463383)
22. Catalone B. J., Ferguson M. L., Miller S. R., Malamud D., Kish-Catalone T., Thakkar N. J., Krebs F. C., Howett M. K., Wigdahl B., Prolonged exposure to the candidate microbicide C31G differentially reduces cellular sensitivity to agent re-exposure Biomedicine and Pharmacotherapy 2005 59 8 460 468 (Pubitemid 41383841)
23. Catalone B. J., Miller S. R., Ferguson M. L., Malamud D., Kish-Catalone T., Thakkar N. J., Krebs F. C., Howett M. K., Wigdahl B., Toxicity, inflammation, and anti-human immunodeficiency virus type 1 activity following exposure to chemical moieties of C31G Biomedicine and Pharmacotherapy 2005 59 8 430 437 (Pubitemid 41383836)
24. O'Malley L. P., Collins A. N., White G. F., Biodegradability of end-groups of the biocide polyhexamethylene biguanide (PHMB) assessed using model compounds Journal of Industrial Microbiology and Biotechnology 2006 33 8 677 684 (Pubitemid 44065572)
25. Tien D., Schnaare R. L., Kang F., Cohl G., McCormick T. J., Moench T. R., Doncel G., Watson K., Buckheit R. W., Lewis M. G., Schwartz J., Douville K., Romano J. W., In vitro and in vivo characterization of a potential universal placebo designed for use in vaginal microbicide clinical trials AIDS Research and Human Retroviruses 2005 21 10 845 853 (Pubitemid 43150316)
26. Moench T. R., Mumper R. J., Hoen T. E., Sun M., Cone R. A., Microbicide excipients can greatly increase susceptibility to genital herpes transmission in the mouse BMC Infectious Diseases 2010 10, article 331
27. Mauck C. K., Weiner D. H., Creinin M. D., Barnhart K. T., Callahan M. M., Bax R., A randomized Phase I vaginal safety study of three concentrations of C31G vs. Extra Strength Gynol II Contraception 2004 70 3 233 240 (Pubitemid 39119986)
28. Mauck C. K., Frezieres R. G., Walsh T. L., Schmitz S. W., Callahan M. M., Bax R., Male tolerance study of 1 C31G Contraception 2004 70 3 221 225
29. Mauck C. K., Creinin M. D., Barnhart K. T., Ballagh S. A., Archer D. F., Callahan M. M., Schmitz S. W., Bax R., A Phase I comparative postcoital testing study of three concentrations of C31G Contraception 2004 70 3 227 231 (Pubitemid 39119985)
30. Patel S., Hazrati E., Cheshenko N., Galen B., Yang H., Guzman E., Wang R., Herold B. C., Keller M. J., Seminal plasma reduces the effectiveness of topical polyanionic microbicides Journal of Infectious Diseases 2007 196 9 1394 1402 (Pubitemid 351412013)
31. Neurath A. R., Strick N., Li Y. Y., Role of seminal plasma in the anti-HIV-1 activity of candidate microbicides BMC Infectious Diseases 2006 6, article 150
32. Martellini J. A., Cole A. L., Venkataraman N., Quinn G. A., Svoboda P., Gangrade B. K., Pohl J., Srensen O. E., Cole A. M., Cationic polypeptides contribute to the anti-HIV-1 activity of human seminal plasma FASEB Journal 2009 23 10 3609 3618